

BEAUMONT HEALTH GUIDELINES FOR CYTOGENETIC/MOLECULAR TESTING OF HEMATOPOIETIC MALIGNANCY - **UPDATED**

Effective Date: October 14, 2018

With the expanding discovery of new genetic markers, it became imperative to have a test protocol in place to ensure compliance with NCCN guidelines and WHO guidelines. Thus, a multidisciplinary committee was formed by Beaumont Laboratory to standardize cytogenetic and molecular testing for hematopoietic malignancy across the hospital system. This Laboratory Bulletin summarizes the current testing protocol and ancillary tests that will automatically be ordered by the pathologists in all new diagnoses of hematopoietic malignancy.

Laboratory Bulletin

Acute Lymphoblastic Leukemia	<ul style="list-style-type: none"> • Karyotype • ALL FISH Panel [4,10,17 trisomy; t(9;22); 11q23 rearrangement; t(12;21); t(1;19); iAMP21 per Children's Oncology Group protocol] • RT-PCR for BCR-ABL1
Acute Myeloid Leukemia	<ul style="list-style-type: none"> • Karyotype • Limited AML FISH Panel [CBFB gene rearrangement for inv16/t(16;16), p53, t(15;17), MLL, t(9;22)] on all • Expanded FISH panel upon request to also include t(8;21) and 3q26 rearrangement • NPM1, FLT3, CEBPA, IDH1, IDH2, KIT (Exon 8, 17)
Myelodysplastic Syndrome	<ul style="list-style-type: none"> • Karyotype • FISH only upon request or at discretion of pathologist or if traditional karyotype obtained <20 metaphases [MDS FISH Panel: trisomy 8,del(20q),monosomy 5/del(5q),monosomy 7/del(7q),3q26 rearrangement, monosomy 13/del(13q), MLL,p53]
Myeloproliferative Neoplasms	<ul style="list-style-type: none"> • Karyotype • FISH or RT-PCR for BCR-ABL1 • JAK2, if negative CALR, MPL (ET and MF) and JAK2 Exon 12 (PV)
Eosinophilia associated with myeloid/lymphoid neoplasms	<ul style="list-style-type: none"> • Eosinophilia FISH Panel [FIP1L1/PDGFRB, PDGFRB and FGFR1 rearrangements]
Plasma Cell Myeloma	<ul style="list-style-type: none"> • Karyotype • Myeloma FISH Panel [CDKN2C/CKS1B for chromosome 1q rearrangement, CEP3/7 for hyperdiploidy, monosomy 13/del(13q), p53, IGH/CCND1 with reflex to IGH/FGFR3, IGH/MAF, and IGH/MAFB]
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma	<ul style="list-style-type: none"> • CLL FISH Panel [MYB/CEP6, trisomy 12, p53,ATM,monosomy 13/del(13q), IGH/CCND1] • Karyotype
Diffuse Large B-cell Lymphoma	<ul style="list-style-type: none"> • FISH for double hit lymphoma all cases[MYC, IGH/BCL2, BCL6] • Karyotype optional
Burkitt Lymphoma	<ul style="list-style-type: none"> • [FISH for IGH/MYC with reflex to IGK/MYC and IGL/MYC]
Hairy Cell Leukemia	<ul style="list-style-type: none"> • BRAF V600E (send out)

Continued

Beaumont

Beaumont Laboratory

Dearborn • Farmington Hills • Grosse Pointe • Royal Oak • Taylor • Trenton • Troy • Wayne

Continued

Lymphoplasmacytic Lymphoma	<ul style="list-style-type: none">• MYD88 L265P• CXCR4 at request of ordering physician for patient's being considered for ibrutinib
Gastric Malt Lymphoma	<ul style="list-style-type: none">• H. pylori testing (also should be performed in gastric DLBCL)• If positive for H. pylori; FISH for t(11;18) will be performed
T-cell Prolymphocytic Leukemia	<ul style="list-style-type: none">• T-cell leukemia/lymphoma FISH Panel [TCL1 (14q32),TCRAD (14q11), TCRB (7q434), and TLX3 (5q32) rearrangements; chromosome 8 abnormalities; del(9p)]
Peripheral T-cell Lymphoma and Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders	<ul style="list-style-type: none">• FISH for DUSP22 if ALK negative ALCL consideration (paraffin only)
Other lymphomas	<ul style="list-style-type: none">• Additional cytogenetic and molecular testing is useful under certain circumstances and will be performed at discretion of pathologist; nothing routinely performed or required• NHL FISH Panel (IGH/CCND1, IGH/BCL2, MALT1, MYC, BCL6)

Date submitted:

October 5, 2018

Submitted by:

Beaumont Laboratory Clinical Practice Utilization Committee

Chairs: Vaishali Pansare, MD, Chief Medical Director, Troy

Masood Siddiqui, Masood, MD, Medical Director, Specimen Receiving, Troy